Perspectives on HAART: Switch maintenance therapy

International Journal of STD and AIDS

Volumn 14, Issue 9, 2003, Pages 577-582

  Leen, C L S ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

HAART; Simplification; Switch maintenance therapy

Indexed keywords

ABACAVIR; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPID STORAGE; LIPOATROPHY; LIVER DISEASE; MAINTENANCE THERAPY; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPODYSTROPHY; METABOLIC DISEASES; NEVIRAPINE; OXAZINES; PATIENT COMPLIANCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0041334066     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203322301004     Document Type: Review

References (57)

1. Palella Jr, FR, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;383:853-60
2. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virologic failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353:863-8
3. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS 2000;14:499-507
4. Mackie NE, Sabin C, Weber J. Discontinuation of therapy in patients receiving first-line HAART regimens. 6th International Congress on Drug Therapy in HIV infection. Glasgow, 2002 (Abs P23)
5. Jordan J, Cahn P, Vibhagool A, et al. Patient satisfaction with treatment is associated with adherence and treatment continuation. Results from CNA 3014. [Abs 1011]. In: Programs and abstracts of 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002
6. Bartlett J, Demasi R, Quinn J, et al. Meta-analysis of efficacy of triple combination therapy in antiretroviral naive HIV-1 infected adults. 7th CROI; 2000; San Francisco. (Abs 519)
7. Stone VE. Potential impact of once daily regimens on adherence to HAART. Abs 486 40th Annual Meeting of the Infectious Diseases Society of America, Chicago 24-27 October, 2002
8. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life in human immunodeficiency virus infection. Am J Med 2002;113:229-32
9. Becker S, Rachlis A, Gill J, et al. Successful substitution of protease inhibitors with SUSTIVA (efavirenz) in patients with undetectable plasma HIV-1 RNA levels: results of a prospective, randomized, multicenter, open label study (DMP 266-049) [abstract 20]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000
10. Patterson P, Krolewiecki A, Ochoa C, et al. A randomized study of treatment simplification with nevirapine or efavirenz in patients responding to a protease inhibitor-based combination [Abs 58]. In: Programs and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001
11. Martinez E, Podzamczer D, Ribera E, et al. Switching protease inhibitors to nevirapine, efavirenz or abacavir: a randomized, multicenter, open-label simplification trial [Abs LB17]. In: Programs and abstracts of the 9th conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002
12. Katlama C, Staszewski S, Cluck N, et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomized, multicenter, open label study (DMP 006-027) [Abs LbPeB7044]. In: Programs and abstracts of the 13th International Conference on AIDS (Durban, South Africa). Rome: International AIDS Society, 2000:283
13. Martinez E, Romeu J, Garcia-Viejo A, et al. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy [Abs 668]. In: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health, 2001
14. Negredo E, Cruz L, Paredes R, et al. Virological, immunological, and clinical impact of switching from protease inhibitors (PI) to nevirapine (NVP) or efavirenz (EFV) in patients with HIV infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10
15. Patterson P, Krolewiecki A, Ochoa C, et al. A randomized study of treatment simplification with nevirapine or efavirenz in patients responding to a protease inhibitor-based combination [abs 58]. In: Programs and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment (Buenos Aires). Stockholm: International AIDS Society, 2001
16. Martinez E, Podzamczer D, Ribera E, et al. Switching protease inhibitors to nevirapine, efavirenz or abacavir: a randomized, multicenter, open-label simplification trial [Abs LB17]. In: Programs and abstracts of the 9th conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retroviruses and Human Health, 2002
17. Ruiz L, Negredo E, Domingo P, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36
18. Barreiro P, Soriano V, Blanco F, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12
19. Masquelier B, Neau D, Chene G, et al. Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA. J Acquir Immune Defic Syndr 2001;28:309-12
20. Clumeck N, Goebel F, Rozenbaum W, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1-RNA. AIDS 2001;15:1517-26
21. Pulvirenti J, Godwin D, Slater L, et al. Simplification of protease inhibitor-containing HAART regimen with abacavir maintains viral suppression and favourable adherence in HIV-1 infected adults [abstract 689]. Clin Infect Dis 2001;33:1206
22. Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002;185:1251-60
23. Pellegrin I, Caumont A, Garrigue I, et al. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 2003;187:38-46
24. Miller JE, Emery S, French M, et al. The Australian prevalence survey of lipodystrophy syndrome (Abs 201). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, 2000
25. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV associated lipodystrophy in an ambulatory population. AIDS 2001;15:1389-98
26. Bernasconi E, Boubaker K, Sudre P, et al. Metabolic side effects of antiretroviral therapy in the Swiss Cohort study. (abstract ThOrB703). XIII International AIDS Conference, Durban, South Africa. 9-14 July, 2000
27. Martinez E, Conger I, Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10
28. Martinez E, Garcia-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated patients with lipodystrophy. Clin Infect Dis 2000;31:1266-73
29. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy; a randomised controlled open label multicentre study. AIDS 2001;15:1811-22
30. Moyle GJ, Baldwin C, Mandalia S, et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single arm observational cohort [letter]. J Acquir Immune Defic Syndr 2001;28:399-401
31. Lafon E, Bani Sadr F, Chandemerle C, et al. LIPSTOP study: evolution of clinical lipodystrophy, blood lipids, visceral and subcutaneous adipose tissue after switching from protease inhibitor to efavirenz in HIV-1-infected patients [abs 1535]. In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 2000
32. Tebas P, Yarasheski K, Henry K, et al. Evolution of multiple metabolic parameters after the switch of protease inhibitors to nevirapine [Abs ThPpB1485]. In: Programs and abstracts of the 13th International Conference on AIDS (Durban, South Africa). Rome: International AIDS Society, 2000:283
33. Schamberlan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA panel. J AIDS 2002;31: 257-75
34. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-9
35. Walli R, Hertford O, Michi GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998;12:F167-F173
36. Mynarcik DC, McNurlan MA, Steigbigel RT. Association of severe insulin resistance with both loss of limb fat and elevated tumor necrosis factor receptor levels in HIV lipodystrophy. J AIDS 2000;25:312-21
37. Walli RK, Michl GM, Bogner JR. Improvement of HAART-associated insulin resistance and dyslipidaemia after replacement of protease inhibitor with abacavir. Eur J Med Res 2001;6:413-21
38. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis and prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9
39. Berthold HK, Parhofer KG, Ritter MM, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;246:567-75
40. Tashima K, Stryker R, Skiest D, et al. Lipid profiles and clinical lipodystrophy in study 006 patients (abstract 1304). In: Programs and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999
41. van der Valk M, Kastelein H, Murphy RL, et al. Nevirapine containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-14
42. Friis-Møller N, Weber R, D'Arminio Monforte A, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: The D:A:D Study. Abstract 130 In: Programs and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, 2003
43. Fisac C Fumero E, Crespo M, et al. A randomised trial of metabolic and body composition changes in patients switching from PI containing regimen to abacavir, efavirenz, nevirapine (abstract 699). In: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic infections. Seattle, 2002
44. Katlama C, Staszewski S, Cluck N, et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomized, multicenter, open label study (DMP 006-027) [abstract LbPeB7044]. In: Programs and abstracts of the 13th International Conference on AIDS, (Durban, South Africa). Rome: International AIDS Society, 2000:283
45. Estrada V, de Vilar N, Larrad MT, et al. Long term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 2002;35:68-76
46. Bonnet EP, Yovanovitch JD, Mularcryk MB, et al. Switching from protease inhibitors to efavirenz does not improve clinical lipodystrophy and hyperlipidaemia in HIV infected patients (Abs 1538). In: Programs and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000
47. Negredo E, Masana L, Ribalta J, et al. Nuclear magnetic resonance (NMR)-assessed changes of lipid metabolism in HIV-1 infected patients with lipodystrophy after switching the protease inhibitor by nevirapine (Abs 485). In: Programs and abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires, 2001
48. Maggiolo F, Arici A, Callegaro A, et al. Nevirapine to simply HAART in PI-experienced, successfully treated patients (Abs 38). In: Programs and abstracts 6th International Congress on Drug Therapy in HIV infection. Glasgow, 2002
49. Lafeuillade A, Mamet JP, Chéret A, et al. Comparison of the metabolic disorders and clinical lipodystrophy 48 weeks after switching from highly active antiretroviral therapy to Trizivir versus continued highly active antiretroviral therapy (Abs 28). In: Programs and abstracts of the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy (Athens). Antiviral Therapy 2001;6(Suppl 4):20-1 Abstr 28
50. Mallal S, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2002;14:1309-16
51. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS 1999;12:1659-67
52. Brinkman K, Smeitink JA, Romjin JA, et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-15
53. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomised trial. JAMA 2002;288:207-15
54. John M, James I, Mckinnon E, et al. A randomised controlled, open label study of revision of antiretroviral regimen containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48 week data (Abs 700-T). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002
55. McComsey G, Lonergan T, Fissher R, et al. Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) to zidovudine (ZDV) (Abs 701-T). 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002
56. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy (Abs 52). In: Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, 2000
57. McComsey G, Ward D, Hessenthaler S, et al. CT scan findings at 48 weeks confirm further regression of lipoatrophy following the substitution of stavudine (d4T) with either abacavir (ABC) or zidovudine (ZDV). 42nd ICAAC, San Diego, 2002, #H-1929